The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer
Abstract
Aim: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. Materials & methods: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). Results: THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis. Discussion: We found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples. Conclusion: Our preliminary findings support the diagnostic and prognostic values of THOR in pancreatic cancer.
Additional Information
© 2017 Future Medicine Ltd. Published Online:11 Oct 2017. JD Apolónio and VP Roberto were the recipients of PD/BD/105899/2014 FCT and LPCC-Fundação PT2016 fellowships, respectively. RA De Mello is advisory board/speaker for Pfizer, Zodiac, AstraZeneca, Novartis; he has a research grant from the CNPQ (Brazilian National Council for Science and Technology, Brasília, DF, Brazil, Number: 402621/2016-6). We confirm that none of authors of this manuscript have any conflicts of interest to declare associated with this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.Additional details
- Eprint ID
- 82370
- Resolver ID
- CaltechAUTHORS:20171016-124607098
- PD/BD/105899/2014
- Fundação para a Ciência e a Tecnologia (FCT)
- LPCC-Fundação PT2016
- 402621/2016-6
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Created
-
2017-10-17Created from EPrint's datestamp field
- Updated
-
2021-11-15Created from EPrint's last_modified field